These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 25733984)

  • 21. Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia.
    Trzepacz PT; Yu P; Sun J; Schuh K; Case M; Witte MM; Hochstetler H; Hake A;
    Neurobiol Aging; 2014 Jan; 35(1):143-51. PubMed ID: 23954175
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FDG and Amyloid PET in Cognitively Normal Individuals at Risk for Late-Onset Alzheimer's Disease.
    Murray J; Tsui WH; Li Y; McHugh P; Williams S; Cummings M; Pirraglia E; Solnes L; Osorio R; Glodzik L; Vallabhajosula S; Drzezga A; Minoshima S; de Leon MJ; Mosconi L
    Adv J Mol Imaging; 2014 Apr; 4(2):15-26. PubMed ID: 25530915
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regional expansion of hypometabolism in Alzheimer's disease follows amyloid deposition with temporal delay.
    Förster S; Grimmer T; Miederer I; Henriksen G; Yousefi BH; Graner P; Wester HJ; Förstl H; Kurz A; Dickerson BC; Bartenstein P; Drzezga A
    Biol Psychiatry; 2012 May; 71(9):792-7. PubMed ID: 21679929
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Pilot Study on Clinical and Neuroimaging Characteristics of Chinese Posterior Cortical Atrophy: Comparison with Typical Alzheimer's Disease.
    Wang XD; Lu H; Shi Z; Cai L; Liu S; Liu S; Han T; Wang Y; Zhou Y; Wang X; Gao S; Ji Y
    PLoS One; 2015; 10(8):e0134956. PubMed ID: 26267071
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simultaneous PET-MRI Studies of the Concordance of Atrophy and Hypometabolism in Syndromic Variants of Alzheimer's Disease and Frontotemporal Dementia: An Extended Case Series.
    Moodley KK; Perani D; Minati L; Della Rosa PA; Pennycook F; Dickson JC; Barnes A; Contarino VE; Michopoulou S; D'Incerti L; Good C; Fallanca F; Vanoli EG; Ell PJ; Chan D
    J Alzheimers Dis; 2015; 46(3):639-53. PubMed ID: 26402512
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolic positron-emission tomography/magnetic resonance imaging in primary progressive aphasia and frontotemporal lobar degeneration subtypes: Reassessment of expected [
    Franceschi AM; Naser-Tavakolian K; Clifton M; Bangiyev L; Cruciata G; Clouston S; Franceschi D
    World J Nucl Med; 2021; 20(3):294-304. PubMed ID: 34703399
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amyloid deposition in early onset versus late onset Alzheimer's disease.
    Cho H; Seo SW; Kim JH; Suh MK; Lee JH; Choe YS; Lee KH; Kim JS; Kim GH; Noh Y; Ye BS; Kim HJ; Yoon CW; Chin J; Na DL
    J Alzheimers Dis; 2013; 35(4):813-21. PubMed ID: 23507771
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.
    Kerbler GM; Fripp J; Rowe CC; Villemagne VL; Salvado O; Rose S; Coulson EJ;
    Neuroimage Clin; 2015; 7():105-13. PubMed ID: 25610772
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of molecular imaging on the diagnostic process in a memory clinic.
    Ossenkoppele R; Prins ND; Pijnenburg YA; Lemstra AW; van der Flier WM; Adriaanse SF; Windhorst AD; Handels RL; Wolfs CA; Aalten P; Verhey FR; Verbeek MM; van Buchem MA; Hoekstra OS; Lammertsma AA; Scheltens P; van Berckel BN
    Alzheimers Dement; 2013 Jul; 9(4):414-21. PubMed ID: 23164552
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types.
    Villemagne VL; Ataka S; Mizuno T; Brooks WS; Wada Y; Kondo M; Jones G; Watanabe Y; Mulligan R; Nakagawa M; Miki T; Shimada H; O'Keefe GJ; Masters CL; Mori H; Rowe CC
    Arch Neurol; 2009 Dec; 66(12):1537-44. PubMed ID: 20008660
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Discourse Profile in Corticobasal Syndrome: A Comprehensive Clinical and Biomarker Approach.
    de Almeida IJ; Silagi ML; Carthery-Goulart MT; Parmera JB; Cecchini MA; Coutinho AM; Dozzi Brucki SM; Nitrini R; Schochat E
    Brain Sci; 2022 Dec; 12(12):. PubMed ID: 36552165
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In Alzheimer's disease, hypometabolism in low-amyloid brain regions may be a functional consequence of pathologies in connected brain regions.
    Klupp E; Förster S; Grimmer T; Tahmasian M; Yakushev I; Sorg C; Yousefi BH; Drzezga A
    Brain Connect; 2014 Jun; 4(5):371-83. PubMed ID: 24870443
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Asymmetries of amyloid-β burden and neuronal dysfunction are positively correlated in Alzheimer's disease.
    Frings L; Hellwig S; Spehl TS; Bormann T; Buchert R; Vach W; Minkova L; Heimbach B; Klöppel S; Meyer PT
    Brain; 2015 Oct; 138(Pt 10):3089-99. PubMed ID: 26280595
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 18F-FDG PET Improves Diagnosis in Patients with Focal-Onset Dementias.
    Taswell C; Villemagne VL; Yates P; Shimada H; Leyton CE; Ballard KJ; Piguet O; Burrell JR; Hodges JR; Rowe CC
    J Nucl Med; 2015 Oct; 56(10):1547-53. PubMed ID: 26251415
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enrichment through biomarkers in clinical trials of Alzheimer's drugs in patients with mild cognitive impairment.
    Lorenzi M; Donohue M; Paternicò D; Scarpazza C; Ostrowitzki S; Blin O; Irving E; Frisoni GB;
    Neurobiol Aging; 2010 Aug; 31(8):1443-51, 1451.e1. PubMed ID: 20541287
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.
    Engler H; Forsberg A; Almkvist O; Blomquist G; Larsson E; Savitcheva I; Wall A; Ringheim A; Långström B; Nordberg A
    Brain; 2006 Nov; 129(Pt 11):2856-66. PubMed ID: 16854944
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease.
    Ziolko SK; Weissfeld LA; Klunk WE; Mathis CA; Hoge JA; Lopresti BJ; DeKosky ST; Price JC
    Neuroimage; 2006 Oct; 33(1):94-102. PubMed ID: 16905334
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential Synaptic Loss in β-Amyloid Positive Versus β-Amyloid Negative Corticobasal Syndrome.
    Holland N; Savulich G; Jones PS; Whiteside DJ; Street D; Swann P; Naessens M; Malpetti M; Hong YT; Fryer TD; Rittman T; Mulroy E; Aigbirhio FI; Bhatia KP; O'Brien JT; Rowe JB
    Mov Disord; 2024 Apr; ():. PubMed ID: 38671545
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnosing Corticobasal Syndrome Based on the Presence of Visual Hallucinations and Imaging with Amyloid Positron Emission Tomography.
    Nishida H; Hayashi Y; Harada N; Sakurai T; Wakida K
    Intern Med; 2018 Feb; 57(4):605-611. PubMed ID: 29269636
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Utility of perfusion PET measures to assess neuronal injury in Alzheimer's disease.
    Joseph-Mathurin N; Su Y; Blazey TM; Jasielec M; Vlassenko A; Friedrichsen K; Gordon BA; Hornbeck RC; Cash L; Ances BM; Veale T; Cash DM; Brickman AM; Buckles V; Cairns NJ; Cruchaga C; Goate A; Jack CR; Karch C; Klunk W; Koeppe RA; Marcus DS; Mayeux R; McDade E; Noble JM; Ringman J; Saykin AJ; Thompson PM; Xiong C; Morris JC; Bateman RJ; Benzinger TLS;
    Alzheimers Dement (Amst); 2018; 10():669-677. PubMed ID: 30417072
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.